Vasopressin for vasopressor-dependent septic shock

American Journal of Health-System Pharmacy

Volumn 62, Issue 18, 2005, Pages 1931-1936

  Szumita, Paul M ^a   Enfanto, Christopher M ^a   Greenwood, Bonnie ^a   Wechsler, Michael E ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; NORADRENALIN; VASOPRESSIN;

CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HEART ARREST; HEART ATRIUM ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPONATREMIA; LIMB ISCHEMIA; LIVER DYSFUNCTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SEPTIC SHOCK; SKIN DEFECT; TACHYCARDIA; VASODILATATION; VENOUS THROMBOEMBOLISM;

EID: 24944479892     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp040614     Document Type: Review

References (23)

1. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med. 2001; 345:588-95.
2. Dellinger RP, Carlet JM, Masur H et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004; 32:858-71.
3. Mutlu GM, Factor P. Role of vasopressin in the management of septic shock. Intensive Care Med. 2004; 30:1276-91.
4. Landry DW, Levin HR, Gallant EM et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation. 1997; 95:1122-5.
5. Holmes CL, Patel BM, Russell JA et al. Physiology of vasopressin relevant to management of septic shock. Chest. 2001; 120:989-1002.
6. Jackson EK. Vasopressin and other agents affecting the renal conservation of water. In: Hardman JG, Limbird LE, Gilman AG, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill; 2001.
7. Landry DW, Levin HR, Gallant EM et al. Vasopressin presser hypersensitivity in vasodilatory septic shock. Crit Care Med. 1997; 25:1279-82.
8. Holmes CL, Walley KR, Chittock DR et al. The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med. 2001; 27:1416-21.
9. Dunser MW, Mayr AJ, Ulmer H et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation. 2003; 107:2313-9.
10. Klinzig S, Simon M, Reinhart K et al. High-dose vasopressin is not superior to norepinephrine in septic shock. Crit Care Med. 2003; 31:2646-50.
11. Hall LG, Oyen LJ, Taner CB et al. Fixed-dose vasopressin compared with titrated dopamine and norepinephrine as initial vasopressor therapy for septic shock. Pharmacotherapy. 2004; 24:1002-12.
12. Obritsch M, Jung R, Fish D et al. Effects of continuous vasopressin infusion in patients with septic shock. Ann Pharmacother. 2004; 38:1117-22.
13. Dunser MW, Mayr AJ, Ulmer H et al. The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: a retrospective analysis. Anesth Analg. 2001; 93:7-13.
14. Patel BM, Chittock DR, Russell JA et al. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology. 2002; 96:576-82.
15. Malay MB, Ashton RC Jr, Landry DW et al. Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma. 1999; 47:699-705.
16. Holmes CL, Walley KR, Chittock DR et al. The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med. 2001; 27:1416-21.
17. Tsuneyoshi I, Yamada H, Kakihana Y et al. Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med. 2001; 29:487-93.
18. Dunser MW, Mayr AJ, Tur A et al. Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: incidence and risk factors. Crit Care Med. 2003; 31:1394-8.
19. Rudichenko VM, Beierwaltes WH. Arginine vasopressin-induced renal vasodilation mediated by nitric oxide. J Vasc Res. 1995; 32:100-5.
20. Gutkowska J, Jankowski M, Lambert C et al. Oxytocin releases atrial natriuretic peptide by combining with oxytocin receptors in the heart. Proc Natl Acad Sci U S A. 1997; 94:11704-9.
21. Van Haren F, Rozendaal F, Van der Hoeven J. The effect of vasopressin on gastric perfusion in catecholamine-dependent patients in septic shock. Chest. 2003; 124:2256-60.
22. Sirinek KR, Levine BA. High dose vasopressin for acute variceal hemorrhage. Clinical advantages without adverse effects. Arch Surg. 1988; 123:876-80.
23. Greenwald RA, Rheingold OJ, Chiprut RO et al. Local gangrene: a complication of peripheral Pitressin therapy for bleeding esophageal varices. Gastroenterology. 1978; 74:744-6.